Cataract prevention. Therapeutic approaches and critical review of current status;Kataraktprävention. Therapeutische ansätze und kritische betrachtung des erreichten

Ophthalmologe

Volumn 100, Issue 3, 2003, Pages 176-180

  Wegener, A ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Aging; Anti cataract drug; Lens metabolism; Medical therapy; Prevention

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; FOOD ADDITIVE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

AGING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATARACT; CATARACTOGENESIS; DRUG EFFECT; DRUG MARKETING; ENZYME INHIBITION; HUMAN; LENS EPITHELIUM; PATHOPHYSIOLOGY; RESEARCH; RISK FACTOR;

ALDEHYDE REDUCTASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CATARACT; CLINICAL TRIALS; DRUGS, NON-PRESCRIPTION; HUMANS; LENS, CRYSTALLINE; TREATMENT OUTCOME;

EID: 0038613863     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-003-0787-1     Document Type: Article

References (33)

1. Ajiboye R, Harding JJ (1989) The non-enzymic glycosylation of bovine lens proteins by glycosamine and its inhibition by aspirin, ibuprofen and glutathione. Exp Eye Res 49:31-41
2. AREDS (2001) Report No.9: A Randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss. Arch Ophthalmol 119:1439-1452
3. Augustin A, Spitznas M, Breipohl W, Wegener A (1992) Evidence for the prevention of oxidative tissue damage in the inner eye by vitamin E and vitamin C. Ger J Ophthal 1, 394-398
4. Hockwin O (1981) Zur Pathogenese und Therapie der Alterskatarakt: Historische Aspekte und neue Vorstellungen. Hist Ophthal Intern 2:115-131
5. Hockwin O (1982) Multifaktorielle Genese der Linsentrübungen im Alter und medikamentöses Vorgehen. In: Hockwin O (Hrsg) Altern der Linse. Symposium Strasbourg, Mayr, Miesbach, S 81-88
6. Hockwin O (1987) Drug treatment of cataracts. Medical Therapy p. 223 (1986) Acta XXV Concilium Ophthalmologicum. Kugler & Ghedini, Amsterdam Berkeley Milano, pp 2396-2400
7. Hockwin O (1987) Drug treatment of cataracts. Medical Therapy p. 223 (1986) Acta XXV Concilium Ophthalmologicum. Kugler & Ghedini, Amsterdam Berkeley Milano, pp 2396-2400
8. Hockwin O (1989) Stellenwert der Antikataraktika. In: Gross G (ed) Kongreß-Bericht des DOG-Referates. Augenspiegel 12:18-20
9. Hockwin O, Korte I, Noll E, Heiden M, Konopka R, Hagenah I, Hurtado R (1985) Is it possible to maintain a normal glutathione level in lenses in vitro? Graefe's Arch Clin Exp Ophthalmol 222:142-146
10. Hockwin O, Laser H, De Gregorio M, Carrieri MP (1989) Bendazac lysine in selected types of human senile cataract. A long-term double-masked placebo-controlled clinical trial with multilinear densitometric image analysis of Scheimpflug photographs. Ophthalmic Res 21:141-154
11. Hockwin O, Schmitt C (1990) Stellenwert der Antikataraktika. Fortschr Ophthalmol 87 [Suppl]:9-13
12. Hockwin O, Wegener A (1987) Syn- and cocataractogenesis. A system for testing subliminal lens toxicity. In: Hockwin O (ed) Drug-induced ocular side effects and ocular toxicology, Concepts Toxicol 4:241-249
13. Hockwin O, Wegener A, Sisk DR, Dohrmann B, Kruse M (1984-1985) Efficacy of AL-1576 in preventing naphthalene cataract in three rat strains. A slit lamp and Scheimpflug photographic study. Lens Res 2 (4):321-335
14. Hockwin O, Weigelin E, Baur M, Boutros G (1982) Kontrollierte klinische Studie über die Wirksamkeit von Phakan (R) als Anti-Kataraktmedikament. Fortschr Ophthalmol 79:179-183
15. Holleschau AM, Rathbun WB, Nagasawa HAT (1996) A HPLC radiotracer methodfor assessing the abilizty of L-cysteine prodrugs to maintain glutathione levels in the cultured rat lens. Curr Eye Res 15:501-510
16. Kinoshita J (1974) Mechanisms initiating cataract formation. Invest Ophthal Vis Sci 13:713-724
17. Korte I, Hockwin O, Bass M (1986) Attempts to increase the glutathione content in the lens. Modern trends in aging research. Colloque INSERM-EURAGE Vol. 147:397-402, John Libbey Eurotext Ltd
18. Maclean H (1977) The Melbourne Catalin trial current protocol and some early results. Austr J Ophthalmol 5(3) 183-187
19. Mayer H, Irion KM (1985) Doppelblindstudie über die Wirksamkeit des Kaliumjodid bei der Behandlung des grauen Altersstars. Fortschr Ophthalmol 82:520-523
20. Mayer H, König H (1987) Objektivierte Kataraktentwicklung unter Therpie mit Cytochrom C, Natriumsuccinat, Adenosin, Nicotinsäureamid und Sorbit. Fortschr Ophthalmol 84:261-264
21. Müller HK (1939) Zur Kritik von A. Vogt an meinem Vortrag "Über die Altersstargenese" in Heidelberg. Klin Monatsbl Augenheilkd 102:378-383
22. Ohrloff C, Hockwin O, Korte I, Wegener A (1986) Aldose Reduktase-Hemmer - ein neuer Weg zur Vermeidung diabetischer Linsenveränderungen? Klin Monatsbl Augenheilkd 189:361-362
23. Ohrloff C, Hockwin O, Olson R, Dickmann S (1984) Glutathione peroxidase, glutathione reductase and superoxide dismutase in the aging lens. Curr Eye Res 3:109-115
24. Rathbun WB, Hanson SK (1979) Glutathione metabolic pathway as a scavenging system in the lens. Ophthalmic Res 11:172-176
25. Reddan JR, Giblin FJ, Kadry R, Leverenz V, Dziedzic DC (1999) Protection from oxidative insult in glutathione depleted lens epithelial cells. Exp Eye Res 68:117-127
26. Reddan JR, Sevilla MD, Giblin FJ et al. (1993) The superoxide dismutase mimic TEMPOL protects cultured rabbit lens epithelial cells from hydrogen peroxide insult. Exp Eye Res 56:543-554
27. Riley ML, Harding JJ (1993) The reaction of malondialdehyde with lens proteins and the protective effect of aspirin. Biochem Biophys Acta 1158:107-112
28. Roberts KA, Harding JJ (1990) Ibuprofen, a putative anti-cataract drug, protects the lens against cyanate and galactose. Exp Eeye Res 50:157-164
29. Sasaki H, Lin LR, Yokoyama T, Sevilla MD, Reddy VN, Giblin FJ (1998) TEMPOL protects against lens DNA strand breaks and cataract in the X-rayed rabbit. Invest Ophthal Vis Sci 39:544-552
30. Varma SD, Devamanoharan PS (1995) Oxidative denaturation of lens protein: prevention by pyruvate. Ophthalmic Res 27:18-22
31. Varma SD, Richard RD (1988) Ascorbic acid and the eye lens. Ophthalmic Res 20:164-173
32. Wegener A, Pelser M, Ringens C, Hockwin O (1988) Monitoring naphthalene cataracts of rats after topical application of AI-1576 eye drops with the Topcon SL-45. Test for dose-effect relation. Lens Res 5 (1&2):117-127
33. Weigelin E, Hockwin O (1982) Bericht über eine zufallsverteilte, kontrollierte klinische Studie mit PHAKAN®/PHAKOLEN®. In: Hockwin O (ed) Altern der Linse. Symposium Strasbourg. Mayr, Miesbach, S 183-199